Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
John Gerecitano, Carol Portlock, Paul Hamlin, et al.
Blood
|
December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 21, 2024
IL-33 Induces Cellular and Exosomal miR-146a Expression as a Feedback Inhibitor of Mast Cell Function
Marcela T Taruselli, Amina Abdul Qayum, Daniel Abebayehu, et al.
Leukemia & Lymphoma
|
August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy
David Straus, Graham Collins, Jan Walewski, et al.
British Journal of Haematology
|
February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial
Owen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
Owen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
British Journal of Haematology
|
January 21, 2010
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
Craig H Moskowitz, Joachim Yahalom, Andrew D Zelenetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
Craig H Moskowitz, Heiko Schöder, Julie Teruya-Feldstein, et al.
Haematologica
|
August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes
Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.
Blood Cancer Journal
|
June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
Sabela Bobillo, Erel Joffe, David Sermer, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
John Gerecitano, Carol Portlock, Paul Hamlin, et al.
Blood
|
December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 21, 2024
IL-33 Induces Cellular and Exosomal miR-146a Expression as a Feedback Inhibitor of Mast Cell Function
Marcela T Taruselli, Amina Abdul Qayum, Daniel Abebayehu, et al.
Leukemia & Lymphoma
|
August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy
David Straus, Graham Collins, Jan Walewski, et al.
British Journal of Haematology
|
February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial
Owen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
Owen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
British Journal of Haematology
|
January 21, 2010
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
Craig H Moskowitz, Joachim Yahalom, Andrew D Zelenetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
Craig H Moskowitz, Heiko Schöder, Julie Teruya-Feldstein, et al.
Haematologica
|
August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes
Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.
Blood Cancer Journal
|
June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
Sabela Bobillo, Erel Joffe, David Sermer, et al.
Page
of 7